small molecule

CIBINQO

ABROCITINIB

Loss of exclusivityJanuary 2036latest FDA-listed patent expiry

CompanyPfizer →See this company's full patent-cliff portfolio

Drug detail

Brand name	CIBINQO
Active ingredient	ABROCITINIB
Strength	200MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	January 2022
Marketing status	RX

Listed patents

Patent	Expires	Type
9035074	January 2036	substance, product
9549929	February 2034	use U-3195
9545405	February 2034	substance, product

Regulatory exclusivity

Code	Expires
NCE	January 2027
NPP	February 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Pfizer